Know Cancer

or
forgot password

Screening and Identification of Novel Diagnostic and Prognostic Biomarkers on Ovarian Cancers


N/A
15 Years
80 Years
Open (Enrolling)
Female
Ovarian Cancer

Thank you

Trial Information

Screening and Identification of Novel Diagnostic and Prognostic Biomarkers on Ovarian Cancers


Methods:

All of the patients received four to six courses of adjuvant platinum-containing
chemotherapy. Histologic grading was according to International Union against Cancer
criteria (28). The stage of disease was classified according to the International Federation
of Gynecology and Obstetrics (FIGO, 1987). Pelvic and paraaortic lymph node samplings will
be performed, if the disease will be confined to within the ovary or will be without a
ruptured capsule. The histopathologic data, including histologic type and histologic grade,
will be evaluated by a certified pathologist. The maximal diameter of the residual tumor
after surgery will be also recorded. All patients will be followed up at 3-month intervals.


Inclusion Criteria:



- Patients with ovarian carcinoma who undergo hysterectomy, bilateral oophorectomy and
tubal resection, omentectomy, and appendectomy will be enrolled and the clinical data
will be obtained from our hospital.

Exclusion Criteria:

- None

Type of Study:

Interventional

Study Design:

Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Outcome Measure:

overall survival

Outcome Time Frame:

from disease diagnosis to death

Safety Issue:

No

Authority:

Taiwan: Department of Health

Study ID:

200706002R

NCT ID:

NCT00854399

Start Date:

January 2006

Completion Date:

December 2011

Related Keywords:

  • Ovarian Cancer
  • Ovarian Neoplasms

Name

Location